The Gal9/TIM3 signaling pathway is known to inhibit the immune functions of T cells and NK cells (26), suggesting that targeting Gal9 may represent an effective and promising immunotherapy strategy for HCC. This evidence concerns the gene HAVCR2 and hepatocellular carcinoma.